EUVIMEDEUVIMED entdecken
Crossref

Sodium‐Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis

Fu-Shun Yen iD, Ming-Chih Hou iD, James Cheng-Chung Wei iD, Yu-Han Huang iD, Ying-Hsiu Shih iD, Chun-Wei Pan, Sing-Ting Wang, Chii-Min Hwu iD, Chih-Cheng Hsu iD

Diabetes/Metabolism Research and Reviews · 2025

DOI: 10.1002/dmrr.70070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2025. Verfasst von Fu-Shun Yen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Yen's Clinic, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Liver Cirrhosis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Taipei Veterans General Hospital, National Science and Technology Council, R.O.C..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cirrhosis and diabetes mellitus can develop and influence each other. We conducted this study to compare the hepatic outcomes of sodium‐glucose cotransporter 2 (SGLT2) inhibitor use versus no‐use in patients with liver cirrhosis and type 2 diabetes. Materials and Methods We identified patients diagnosed with type 2 diabetes and liver cirrhosis from the Taiwan's National Health Insurance Research Database between 1 January 2000 and 31 December 2021. Multivariable‐adjusted Cox proportional hazard models were used to compare the risks of decompensated cirrhosis, liver failure, cardiovascular events and mortality between SGLT2 inhibitor users and nonusers.

Results

The mean follow‐up period for SGLT2 inhibitor users and nonusers was 2.86 and 2.66 years, respectively. The incidence rates of mortality during follow‐up were 29.97 versus 63.18 per 1000 person‐years for SGLT2 inhibitor users and nonusers, respectively. The multivariable‐adjusted models showed that SGLT2 inhibitor users had lower risks of all‐cause mortality (aHR 0.47, 95% CI 0.42–0.52), decompensated cirrhosis (aHR 0.67 95% CI 0.58–0.77), liver failure (aHR 0.58, 95% CI 0.49–0.69), hepatorenal syndrome (aHR 0.54, 95% CI 0.35–0.85) and major adverse cardiovascular events (aHR 0.80, 95% CI 0.52–0.70) than nonusers. A longer cumulative duration of SGLT2 inhibitors had further lower risks of mortality and decompensated cirrhosis.

Conclusions

This nationwide cohort study showed that SGLT2 inhibitor use was associated with a significantly lower risk of mortality, decompensated cirrhosis, liver failure and cardiovascular events in patients with compensated liver cirrhosis and type 2 diabetes. SGLT2 inhibitors may be an option for diabetes management in patients with compensated liver cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsLiver CirrhosisDiabetes Mellitus, Type 2HumansMaleFemaleMiddle AgedTaiwanAgedFollow-Up StudiesPrognosisRetrospective StudiesCardiovascular DiseasesIncidence

Stichwörter der Autor:innen

all‐cause mortalitydecompensated cirrhosishepatic failuretype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Dr. Yen's Clinic, Taoyuan, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.

ORCID-Profile: Fu-Shun Yen, Ming-Chih Hou, James Cheng-Chung Wei, Yu-Han Huang, Ying-Hsiu Shih, Chii-Min Hwu, Chih-Cheng Hsu

Förderung

  • Taipei Veterans General Hospital
  • National Science and Technology Council, R.O.C.

Zitieren

APA

Yen, F. S., Hou, M. C., Cheng-Chung Wei, J., Huang, Y. H., Shih, Y. H., Pan, C. W., Wang, S. T., Hwu, C. M., & Hsu, C. C. (2025). Sodium‐Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70070

Vancouver

Yen FS, Hou MC, Cheng-Chung Wei J, Huang YH, Shih YH, Pan CW, et al. Sodium‐Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis. Diabetes/Metabolism Research and Reviews. 2025. doi:10.1002/dmrr.70070

BibTeX
@article{Yen2025,
  author = {Yen, Fu-Shun and Hou, Ming-Chih and Cheng-Chung Wei, James and Huang, Yu-Han and Shih, Ying-Hsiu and Pan, Chun-Wei and Wang, Sing-Ting and Hwu, Chii-Min and Hsu, Chih-Cheng},
  title = {Sodium‐Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2025},
  doi = {10.1002/dmrr.70070}
}
Kostenlos starten →